Background-Supravalvular aortic stenosis (SVAS) is caused by mutations in the elastin (ELN) gene and is characterized by abnormal proliferation of vascular smooth muscle cells (SMCs) that can lead to narrowing or blockage of the ascending aorta and other arterial vessels. Having patient-specific SMCs available may facilitate the study of disease mechanisms and development of novel therapeutic interventions. Methods and Results-Here, we report the development of a human induced pluripotent stem cell (iPSC) line from a patient with SVAS caused by the premature termination in exon 10 of the ELN gene resulting from an exon 9 four-nucleotide insertion. We showed that SVAS iPSC-derived SMCs (iPSC-SMCs) had significantly fewer organized networks of smooth muscle ␣-actin filament bundles, a hallmark of mature contractile SMCs, compared with control iPSC-SMCs. The addition of elastin recombinant protein or enhancement of small GTPase RhoA signaling was able to rescue the formation of smooth muscle ␣-actin filament bundles in SVAS iPSC-SMCs. Cell counts and BrdU analysis revealed a significantly higher proliferation rate in SVAS iPSC-SMCs than control iPSC-SMCs. Furthermore, SVAS iPSC-SMCs migrated at a markedly higher rate to the chemotactic agent platelet-derived growth factor compared with the control iPSC-SMCs. We also provided evidence that elevated activity of extracellular signal-regulated kinase 1/2 is required for hyperproliferation of SVAS iPSC-SMCs. The phenotype was confirmed in iPSC-SMCs generated from a patient with deletion of elastin owing to Williams-Beuren syndrome.
S upravalvular aortic stenosis (SVAS) is an autosomaldominant disease characterized by abnormal proliferation of vascular smooth muscle cells (SMCs) that can lead to narrowing or blockage of the ascending aorta and other arterial vessels and a propensity toward sudden cardiac death. 1 The most common underlying causes for SVAS are heterozygous, loss-of-function mutations in the elastin (ELN) gene that produce haploinsufficiency. 2, 3 Patients with Williams-Beuren syndrome (WBS) also display SVAS; these patients are hemizygous for 26 to 28 contiguous genes, including the ELN gene, owing to a 1.5-to 1.8-Mb microdeletion on chromosome 7q11. 23 . Although WBS patients display a more complex phenotype, including craniofacial and other neurobehavioral defects, the spectrum and pathological characteristics of cardiovascular lesions in patients with SVAS and WBS are virtually identical and have been denoted as ELN arteriopathy. 1, 4 
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The encoded product of the ELN gene is the monomeric precursor protein tropoelastin, which is secreted, cross-linked, and organized into an ELN polymer by vascular SMCs. 5 ELN polymers are the main extracellular matrix components deposited in the arterial wall where they endow elastic resilience. Aside from its essential role in providing biomechanical support for blood vessels, ELN plays a critical role in inducing a quiescent contractile state in vascular SMCs by inhibiting cellular proliferation and promoting the organization of actin filament bundles, the scaffold for the contractile apparatus in SMCs. 3, 6 The use of genetic animal models and primary vascular SMCs to study the mechanisms underlying SVAS has been very informative. 3, 6 However, the study of the disease has been significantly hampered by functional differences in SMCs between species, 7 limited accessibility to patient vascular SMCs, rapid loss of SMC properties in primary cell culture, 8 and an inability to model patient-specific disease variations. Thus, it would be very useful to establish a human cell-based model to obtain an abundant and renewable source of functional SMCs for studying the pathogenesis of this disease and for developing patient-specific therapeutic interventions.
The generation of induced pluripotent stem cells (iPSCs) from human adult somatic cells has opened an exciting avenue for disease modeling and regenerative medicine. 9 -11 Recently, several human cardiovascular disease models have been generated from patients with the long-QT, 12, 13 LEOP-ARD, 14 and Hutchinson-Gilford progeria syndromes. 15, 16 In these studies, cardiovascular cells derived from patientspecific iPSCs have recapitulated the pathological features of each disorder and have provided unique human models to study disease mechanisms.
In this study, we report the generation of an iPSC model of SVAS using 2 different ELN mutations. We have found that SVAS iPSC-derived SMCs (iPSC-SMCs) exhibit a lower degree of organized smooth muscle ␣-actin (SM ␣-actin) filament bundles, proliferate at a higher rate, and migrate significantly faster in response to the chemotactic cytokine platelet-derived growth factor (PDGF) than control iPSC-SMCs, recapitulating key pathological features of the human disease. Our results further show that recombinant ELN or enhancement of small GTPase RhoA signaling rescues SM ␣-actin filament bundle formation and that attenuation of extracellular signal-regulated kinase 1/2 (ERK1/2) activity inhibits hyperproliferation of SVAS iPSC-SMCs, providing a promising paradigm to study disease mechanisms and to develop novel personalized therapies.
Methods

Establishment of Patient-Derived iPSCs
Human iPSC clones were established from vascular SMCs derived by explant outgrowth from excised epicardial coronary arteries of a patient with SVAS and from foreskin fibroblasts from a patient with WBS collected under an Institutional Review Board-approved protocol by transduction with the hSTEMCCA polycistronic lentiviral vector (encoding OCT4, KLF4, SOX2, and c-MYC), as previously published. 17 The human iPSC clones were maintained and propa-gated on mitotically arrested mouse embryonic fibroblast feeder layers. Detailed information of human iPSC generation can be found in the online-only Data Supplement.
Genomic Sequencing
See the online-only Data Supplement for details.
Detection of Mutant ELN mRNA by Inhibiting Nonsense-Mediated Decay
Primary SMCs from a control donor or an SVAS patient were plated and treated with 100 g/mL cycloheximide (Sigma) or dimethyl sulfoxide (control) for 4 hours as previously described. 3, 18 RNA was extracted with Trizol (Life Technologies) following the manufacturer's instructions. Mutant ELN mRNA was detected by the reverse transcription polymerase chain reaction assay using an allele-specific forward primer that contained a 4-nucleotide GTAT insertion at its 3Ј end and an ELN downstream reverse primer. This results in the detection of a polymerase chain reaction product only in the SVAS cells, not in the healthy control cells. GAPDH was used as an internal control. The fragment amplified by polymerase chain reaction was gel extracted (Qiagen) and sequenced to confirm detection of the ELN gene mutation.
Immunofluorescence and Alkaline Phosphatase Staining
Chromosome Integrity (Karyotype) and Fluorescence In Situ Hybridization Analyses
Bisulphite Sequencing
Gene Expression Analysis
Teratoma Formation Assay
SMC Differentiation
SMC differentiation was induced with the use of an embryoid body differentiation system as previously described. 19 Briefly, undifferentiated human iPSCs were dispersed into small cell clumps with 1 mg/mL collagenase IV (Invitrogen) at 37°for 5 minutes. These cells were then cultured in suspension for 6 days in differentiation medium (Dulbecco modified Eagle medium supplemented with 10% FBS from Hyclone, 1% nonessential amino acids, 0.1 mmol/L ␤-mercaptoethanol and 1% L-glutamine) to form embryoid bodies. The embryoid bodies were then plated on 0.1% gelatin-coated culture dishes and cultured with fresh differentiation medium. At 6 days after plating, small clusters were dissociated and transferred to Matrigel-coated plates in SmGM-2 media (Lonza). After 1 week of culture on Matrigel-coated plates, cells were again transferred to 0.1% gelatin-coated culture dishes and cultured with the 5% FBS differentiation medium for at least 5 days to complete differentiation.
Western Blot Analysis
Fluorescence-Activated Cell Sorting Analysis
Rescue of SM ␣-Actin Filament Bundle Formation by ELN Treatment
These procedures were described in a previous study. 6 Briefly, SVAS iPSC-SMCs, WBS iPSC-SMCs, and control iPSC-SMCs were seeded at a density of 50 000 cells per well on a 12-well plate. After attachment, cells were starved in 0.1% BSA (Fisher) in Amniomax Basal Medium (Invitrogen) for 24 hours. Cells were then grown in whole Amniomax medium in the presence or absence of 50 g/mL tropoelastin (Advanced BioMatrix) for 12 to 14 hours, followed by immunofluorescent staining for SM ␣-actin (Sigma) and nuclear counterstaining with Hoechst dye.
Migration of SVAS and WBS iPSC-SMCs
Cell migration was assayed in a modified Boyden chamber system with 6.5-mm transwell polycarbonate chemotaxis filter inserts in a plastic 24-well tissue culture plate (Corning) as previously described. 6 The inserts were covered with a polycarbonate membrane filter (8-m porosity). PDGF-BB (100 ng/mL; R&D Systems) was added to the designated lower chambers. After serum starvation for 24 hours, 2ϫ10 4 iPSC-SMCs grown in SmGM2 media (Lonza) were placed in the upper wells of the chamber and incubated at 37°C in 5% CO 2 overnight in the media containing high-glucose Dulbecco modified Eagle medium (Invitrogen), 1% BSA (Sigma), and 0.5% FBS (Sigma). The cells adhering to the upper surface of the filter were scraped off with cotton swabs, and the cells that had migrated to the lower surface were fixed with 4% paraformaldehyde, stained with Hoechst 33258 (Sigma), and viewed under a fluorescent microscope (Leica). Five to 7 randomly selected fields were counted on each filter. The chemotactic response was calculated as the number of cells that had traversed the filter in response to PDGF and was expressed as fold increase over baseline. Each experiment was repeated at least 3 times.
Blockage of ERK Signaling Pathway and Analysis of Cell Proliferation
Calcium Imaging
Statistical Analysis
Results were reported as meanϮSEM. The Wilcoxon rank-sum test (Mann-Whitney U test) was used to compare 2 groups. The Kruskal-Wallis test was used for 1-factor design with Ն3 groups, and the Scheirer-Ray-Hare test was used for the 2-way design experiments. Both tests were followed by 2-group pairwise comparison with the Wilcoxon rank-sum test. A value of PϽ0.05 was considered statistically significant.
Results
Generation and Characterization of SVAS-iPSCs
Coronary vascular SMCs were isolated from a 39-year-old white man with SVAS who had undergone heart transplantation. The patient is heterozygous for a 4-bp nucleotide (GTAT) insertion in exon 9 of ELN that was predicted to result in a frameshift and a premature termination codon in exon 10 ( Figure 1A ). Premature termination mutations frequently result in the specific degradation of mutant mRNA through nonsense-mediated decay that can be blocked by the protein synthesis inhibitor cycloheximide. 3, 18 Expression of the mutant mRNA was restored by cycloheximide treatment ( Figure IA in the online-only Data Supplement), indicating that the mutant mRNA undergoes nonsense-mediated decay. The cultured vascular SMCs were reprogrammed with a polycistronic lentiviral vector (hSTEMCCA 17 ) expressing OCT4, KLF4, SOX2, and c-MYC to generate SVAS patient- specific iPSC clones ( Figure 1B ). Control human iPSC clones were also created from vascular SMCs from a 12-year-old healthy white boy with the use of the same reprogramming system ( Figure IB in the online-only Data Supplement). Multiple iPSC clones were generated, and 2 SVAS clones and 2 control clones were continuously propagated and used for SMC differentiation and characterization.
The established iPSC clones showed typical, compact human embryonic stem cell morphology ( Figure 1B and Figure To model the SVAS syndrome in a second patient with ELN deficiency and to confirm that the observed disease phenotypes were the result of an ELN defect, we generated and characterized a second iPSC line using the foreskin fibroblasts from a 1-year-old white male patient with WBS who displays SVAS and has a heterozygous, 1.4-Mb microdeletion at chromosome 7q11.23, including the ELN gene. 20 The control human iPSC line was created with the foreskin fibroblasts from a 1-year-old healthy white boy. Multiple iPSC clones were generated, and 2 clones were expanded and analyzed, showing no morphological or phenotypic differences between them; we focused primarily on WBS iPSC clone2 and control iPSC clone2 for our studies (hereafter referred to as WBS iPSCs or control iPSCs). Fluorescence in situ hybridization analysis confirmed the deletion of 1 copy of the ELN gene ( Figure IVA 
SVAS Human iPSC-SMCs Have Defective Actin Filament Bundle Formation
We used an embryoid body differentiation system to induce human iPSC differentiation toward an SMC lineage. 19 This resulted in the production of highly homogenous SMC-like cells identified by the SMC marker calponin 21 Figure VIE in the online-only Data Supplement), suggesting that the tissue origin of iPSC (vascular SMC in this study) and embryonic stem cell (blastocyst) plays a minimal role in contributing to the contractile phenotype of SMCs derived from pluripotent stem cell lines.
To examine whether the defective formation of actin filament bundles in SVAS iPSC-SMCs correlates with an inability to produce sufficient quantities of ELN, we performed immunofluorescence ( Figure 2D and Figure VIIA in the online-only Data Supplement) and Western blot ( Figure 2E and Figure VIIB in the online-only Data Supplement) analyses using an ELN antibody. There was a significantly lower level of ELN protein in SVAS iPSC-SMCs than in control iPSC-SMCs, consistent with haploinsufficiency resulting from the ELN mutation in our patient with SVAS. Similar to the previous studies using cultured primary SMCs, 3,6 our iPSC-SMCs showed a pattern of both intracellular and extracellular ELN staining ( Figure 2D and Figure VIIA in the online-only Data Supplement), possibly reflecting the pattern of ELN expression during in vitro tissue culture. Our findings provide important evidence for decreased ELN expression in the SVAS cells.
Elastin and Small GTPase RhoA Rescue Defective Actin Filament Bundle Formation in SVAS iPSC-SMCs
To investigate whether exogenous ELN is able to rescue the failed formation of actin filament bundles in SVAS iPSC-SMCs, we treated these cells with recombinant tropoelastin protein (ELN monomeric form) for 12 hours and observed that the percentage of SVAS iPSC-SMCs with organized actin filament bundles increased 2.3-fold to 63.6Ϯ4.8% ( Figure 3A The RhoA signaling pathway is known to regulate actin filament bundle formation. 6, 23 Furthermore, activation of RhoA signaling by tropoelastin has been implicated in inducing actin filament bundle formation in murine Eln-null SMCs. 6 We investigated whether activation of RhoA signaling would mimic tropoelastin treatment and rescue the defective actin filament bundle formation in SVAS iPSC-SMCs. Transient transfection of SVAS iPSC-SMCs with constitutively active RhoA (G14V) resulted in a 3.4-fold increase in cells with organized actin filament bundles (67.3Ϯ5.5%) ( Figure 3C and 3D) . In contrast, constitutively active RhoA had no effect on the actin filament bundle formation in control iPSC-SMCs ( Figure VIIIC 
SVAS iPSC-SMCs Proliferate and Migrate at Higher Rates Than Control iPSC-SMCs
It has been reported previously that vascular SMCs derived from ELN-deficient patients or mouse tissue have abnormally high proliferation rates compared with cells derived from healthy controls. 3, 6 We investigated whether SVAS iPSC-SMCs recapitulate the pathology of vascular SMCs derived from primary tissues of patients with SVAS and whether they proliferate at a higher rate than control iPSC-SMCs. Cells were plated at the same density, and growth rates were evaluated by counting cells on days 1, 4, and 7. The number of SVAS iPSC-SMCs was 2.0-fold and 2.9-fold higher than the number of control iPSC-SMCs 4 and 7 days after seeding, respectively ( Figure 4A and Figure IXA in the online-only Data Supplement). BrdU incorporation in SVAS iPSC-SMCs was 2.3-fold higher than in control iPSC-SMCs 7 days after seeding ( Figure 4B and 4C and Figure IXB and IXC in the online-only Data Supplement). These results suggest that SVAS iPSC-SMCs mimic the pathology of vascular SMCs derived from primary tissues of the patient with SVAS and have abnormally high proliferation rates compared with control iPSC-SMCs.
Cytokines and growth factors such as PDGF have been implicated in mediating the subendothelial migration of vascular SMCs in occlusive vascular lesions in Eln-null mice or in patients with vascular diseases. 6, 24 To test whether SVAS iPSC-SMCs migrate at a higher rate than control iPSC-SMCs, we used a modified Boyden chamber chemotaxis assay and observed that SVAS iPSC-SMCs migrated to PDGF at a 2.4-fold higher rate than control iPSC-SMCs did ( Figure 4D and Figure 
WBS iPSC-SMCs Have Defective Actin Filament Bundle Formation and Proliferate and Migrate at Higher Rates Compared With Control iPSC-SMCs
To determine whether the disease phenotypes definitively correspond with the ELN deficiency, we used iPSCs to model SVAS in a second patient. We generated a second iPSC line from a patient with WBS who displays SVAS and has the ELN deletion ( Figure IV in the online-only Data Supplement), consistent with ELN deficiency in our patient with WBS. Importantly, recombinant tropoelastin protein was able to significantly rescue the defective actin filament bundle formation in WBS iPSC-SMCs ( Figure XD and XE in the online-only Data Supplement). In addition, cell counts and BrdU analysis revealed a significantly higher proliferation rate in WBS iPSC-SMCs than in control iPSC-SMCs ( Figure XIA -XIC in the onlineonly Data Supplement). Furthermore, the Boyden chamber chemotaxis assay showed that WBS iPSC-SMCs migrated at a markedly higher rate to PDGF than control iPSC-SMCs ( Figure XID in the online-only Data Supplement). In summary, both WBS and SVAS iPSC-SMCs recapitulate key cardiovascular lesions in WBS and SVAS patients, suggesting that the ELN deficiency tracks with the disease phenotypes.
Elevated ERK1/2 Activity Is Implicated in the Hyperproliferation of SVAS iPSC-SMCs
ERK1/2 signaling has been reported to play an important role in the regulation of vascular SMC proliferation 25,26 but has not been investigated in vascular SMCs from SVAS. We investigated whether elevated ERK1/2 activity correlates with hyperproliferation of SVAS iPSC-SMCs. Analyses of ERK1/2 activity revealed significantly higher ERK phosphorylation in SVAS iPSC-SMCs than in control iPSC-SMCs ( Figure 5A ). Because cyclin D1 is a downstream mediator of ERK signaling during cell cycle control, 27, 28 we measured cyclin D1 expression and observed a significantly higher level of cyclin D1 in SVAS iPSC-SMCs than in control iPSC-SMCs ( Figure 5B ).
To investigate whether elevated activity of ERK1/2 and upregulation of cyclin D1 are required for hyperproliferation of SVAS iPSC-SMCs, we inhibited ERK1/2 activity by treating cells with U0126, a specific inhibitor for MEK 1/2, which activates ERK1/2 through phosphorylation. 27, 28 The addition of U0126 markedly decreased ERK1/2 phosphorylation and cyclin D1 expression in SVAS iPSC-SMCs ( Figure 5A and 5B) . Furthermore, U0126 significantly inhibited the hyperproliferation of SVAS iPSC-SMCs, shown by BrdU incorporation (Figure 5C and 5D ) and direct cell counting ( Figure 5E ). Taken together, these results suggest that elevated activity of ERK signaling is necessary for the hyperproliferation of SVAS iPSC-SMCs.
Discussion
The present study demonstrates the feasibility of using iPSCs to model severe human vascular disease phenotypes caused by genetic defects. We have validated that SMCs derived from SVAS iPSCs have the prototypical hyperproliferation response seen in primary SMCs from SVAS patients ( Figure  4A-4C ). 3 More important, our iPSC model of SVAS has led to the novel finding that SVAS iPSC-SMCs had significantly fewer organized networks of SM ␣-actin filament bundles compared with control iPSC-SMCs (Figure 2A and 2B ). Furthermore, we showed for the first time that either recombinant elastin or small GTPase RhoA is able to rescue defective SM ␣-actin filament bundles in SVAS (Figure 3 ). Furthermore, we made a new discovery that SVAS iPSC-SMCs migrated at a markedly higher rate in response to the chemotactic agent PDGF compared with the control iPSC-SMCs ( Figure 4D ). We also provided novel evidence that ERK1/2 signaling is activated and that its activity is required for hyperproliferation of SVAS iPSC-SMCs ( Figure 5 ). Thus, we not only validate the iPSC approach and the vascular SMC defect from prior studies but also provide new mechanistic insights into SVAS. Our studies specifically suggest that enhancement of SMC actin filament bundle formation by elastin or RhoA and inhibition of cellular proliferation by decreasing ERK1/2 signaling might be potential therapeutic strategies in SVAS patients.
To model SVAS in a second patient and to ensure that the disease phenotypes corresponded with ELN deficiency, we generated a second iPSC line from a patient with WBS who displays SVAS and has a typical WBS microdeletion on chromosome 7q11.23, including ELN ( Figure IV in the online-only Data Supplement). Although WBS patients display a more complex phenotype, the spectrum and pathological characteristics of cardiovascular lesions in patients with SVAS and WBS are virtually identical and have been denoted as ELN arteriopathy. 1, 4 Importantly, WBS iPSC-SMCs recapitulate all 3 defects observed in SVAS iPSC-SMCs (Figures X and XI in the online-only Data Supplement), suggesting that these disease phenotypes correspond well with ELN deficiency in SVAS and WBS patients.
Differences in ELN gene structure and alternative splicing variants between animal models and humans confound the understanding of ELN biology, 29 highlighting the importance of human models to understand SVAS. Previous studies using elastin deficiency mice to study the mechanisms underlying SVAS have also been informative. However, unlike humans with ELN haploinsufficiencies such as SVAS or WBS, Eln ϩ/Ϫ or WBS haploinsufficient mice do not develop aortic occlusive defects. 30, 31 Eln Ϫ/Ϫ -null mice develop fulminant aortic occlusive defects but die on about postnatal day 4.5, 30 preventing the study of ELN deficiency in adult animals. Primary Eln Ϫ/Ϫ vascular SMCs from postnatal day 0.5 pups have defective actin filament bundle formation and proliferate and migrate at a higher rate compared with control SMCs, 6 suggesting a requirement for elastin in vascular morphogenesis. However, although the Eln Ϫ/Ϫnull mouse cells have provided very useful information, they are not SVAS cells and do not replicate the ELN gene dosage defect in human patients. Thus, the mouse model has limitations in the study of the pathophysiology of human disease. It is therefore of great importance to establish a human model for studying the pathogenesis of this disease. Because SVAS and WBS iPSCs can self-perpetuate, they are able to produce unlimited quantities of SMCs and thereby provide a promising model both to study human SVAS and WBS disease mechanisms and to develop new therapies. To the best of our knowledge, this is the first report of a human iPSC-based model of SVAS.
SVAS and WBS iPSC isolates showed similar characteristics of pluripotency, which was confirmed by differentiation into the 3 embryonic germ layers in vitro and by in vivo teratoma formation (Figure 1 SMCs derived from SVAS iPSCs and WBS iPSCs. This might be due to the modest difference in elastin expression between the 2 lines or to the loss of additional gene(s) in the WBS patient that may modify the phenotype. Future efforts will be made to generate additional iPSC lines from multiple SVAS and WBS patients to better assess a correlation between elastin gene dosage and disease phenotype.
Current therapies targeting vascular SMC proliferation such as rapamycin (a protein synthesis and cell cycle inhibitor) tend to have off-target effects such as endothelial cell function inhibition. 32 Previous studies indicate that the rescue of defective actin filament bundle formation via ELN protein inhibits the abnormally high proliferation rate in primary vascular SMCs from Eln-null mice or patients with SVAS. 3, 6 This raises the possibility that inducing assembly of the contractile apparatus such as actin filament bundles may be a more specific and efficacious target for therapy for vascular diseases caused by hyperproliferation of SMCs. The defective actin filament bundle formation (Figure 2A and 2B ) and the ERK-mediated hyperproliferation observed in SVAS iPSC-SMCs ( Figure 5 ) support the notion that enhancing the formation of actin filament bundles might be a preferred target for ameliorating the vascular diseases caused by ERK-mediated hyperproliferation of SMCs. Further studies are warranted to investigate the potential link of defective actin filament bundle formation and hyperactivity of ERK in SVAS iPSC-SMCs. Actin filament bundle formation has been reported to induce nuclear localization of myocardinrelated transcriptional factor cofactors, which inhibit cellular proliferation mediated by serum response factor and ERK signaling, 33, 34 thereby linking actin dynamics with cellular proliferation.
We also provided novel evidence that SVAS and WBS iPSC-SMCs migrated to PDGF at a markedly higher rate than control iPSC-SMCs ( Figure 4D and Figures IXD and XID in the online-only Data Supplement). Formation of lamellipodia at the leading edge of cell is one of the key events regulating directional cell migration. This process requires the assembly of actin subunits into linear polymers and the cross-linking of the filaments. 35 Activation of PI3K/Akt and/or phospholipase C-␥ signaling by PDGF has been implicated in enhancing migration by promoting actin polymerization and the formation of actin networks in lamellipodia. 36, 37 The defective actin filament bundle formation in SVAS and WBS SMCs may result in a larger pool of short fragments or monomeric subunits, which are key substrates for the actin assembly reactions that drive the formation of lamellipodia and promote cell migration. Further studies investigating the mechanism of migration defect in SVAS SMCs may help to unravel the pathological mechanisms of vascular proliferative diseases.
The production of SVAS and WBS iPSC-SMCs also offers a patient-specific platform for small-molecule screening. The effects of small molecules on ELN expression, RhoA activity, or novel signaling pathways could be assessed, or perhaps more directly, their efficacy to increase actin filament bundle formation or decrease cellular proliferation might prove useful. Further studies to elucidate the intracellular signaling events consequent to the exogenous addition of ELN or activation of RhoA and to determine whether those effects are sufficient to alleviate in vivo arterial narrowing represent important future steps for the understanding and treatment of SVAS. Because this SVAS iPSC model recapitulates key pathological features of SVAS resulting from elastin haploinsufficiency, it should facilitate future translational research into SVAS disease mechanisms and novel therapeutic interventions.
